Year: 2021

Henning Beltestad, CEO of Lerøy Seafood Group ASA (LSG), has today November 15h 2021 bought 7,000 shares in LSG at an average price of NOK 70.70 per share. Ownership after this transaction is 49,200 shares in LSG. Please see the attached form for further details. This information is subject to the disclosure requirements pursuant to MAR article 19 and section 5-12 of the Norwegian Securities Trading Act.  AttachmentNotification by CEO

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2021. Third Quarter 2021 and Recent Financial and Operating HighlightsRevenue of $5.1 million for third quarter of 2021, compared to $5.6 million for the third quarter of 2020; Gross margin of 46.2% for third quarter of 2021, improved from 44.2% for the third quarter of 2020; Total cash balance of $1.7 million at quarter end, compared to $4.5 million at year end; Total retail distribution of more than 7,700 stores as of September 30, 2021, an increase from 6,200 stores as of September 30, 2020; Received top 3 awards from LA Weekly: best gummy for sleep,...

Operating income for the third quarter increased 9% year over year to $12.0 million; Non-GAAP operating income for the third quarter increased 14% year over year to a record-breaking $16.2 million Or Yehuda, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) — November 15, 2021 – Magic Software Enterprises Ltd. (NASDAQ and TASE: MGIC), a global provider of IT consulting services and end-to-end integration and application development platforms solutions, announced today its financial results for the third quarter and nine months ended September 30, 2021. Summary Results for Third Quarter 2021 (USD in millions, except per share data)    GAAP     Non-GAAP      Q3 2021     Q3 2020     % Change     Q3 2021     Q3 2020     %  Change  Revenues   $ 120.9     $ 94.9       27.4 %   $ 120.9     $ 94.9       27.4 %Gross Profit   $ 32.6     $ 29.1       12.1 %   $ 34.2     $ 30.7       11.2 %Gross...

Delivers Revenues of $70.1 Million; Up 48% Reported; Up 80% Excluding Contract with U.S. Census Bureau; Driven by Xacta Solutions, Telos ID and Secure Networks Increases Gross Profit 57% to a Record $26.1 Million; Expands Gross Margin 229 Basis Points to 37%, Driven by Every Line of Business Generates $12.5 Million of Cash Flow from Operations and $9.4 Million of Free Cash Flow Updates Guidance with Sales of $240 Million – $245 Million and Adjusted EBITDA of $18 Million – $19 MillionASHBURN, Va., Nov. 15, 2021 (GLOBE NEWSWIRE) — Telos® Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the third quarter 2021. “We saw strong third-quarter results, as we delivered 48% reported sales...

Toronto, Nov. 15, 2021 (GLOBE NEWSWIRE) — D2L Inc. (“D2L”, TSX: DTOL), a global learning technology leader, announced today that it will report financial results for the period ending October 31, 2021 (third quarter, fiscal 2022) after markets close on Wednesday, December 8, 2021. John Baker, Chief Executive Officer, and Melissa Howatson, Chief Financial Officer, will host a conference call to discuss the financial results on Thursday December 9, 2021 at 8:30 a.m (ET), followed by a question-and-answer period. Q3 FISCAL 2022 CONFERENCE CALL DETAILSDate:   Thursday, December 9, 2021Time:   8:30 a.m. (ET)Dial in number:   Canada: 1 (226) 828-7575 or 1 (833) 950-0062 United States: 1 (844) 200-6205Access code: 097764Webcast:   A live webcast will be available at ir.d2l.com/events-and-presentations/events/Replay:   Canada:...

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities. “We recently sharpened the focus of our pipeline strategy, which now includes development of KIO-301, a treatment for a rare disease with a potentially expedited and cost-efficient path to market,” said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. “We anticipate multiple upcoming milestones, including advancing KIO-301 into the clinic next year, reporting topline data from our exploratory dry eye study of KIO-101 and finalizing the design of our registration study for KIO-201 in early 2022.” Recently, Kiora has achieved several milestones,...

SUZHOU, China and PALO ALTO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the third quarter of the year and provided recent business highlights. “We continue to deliver strong research and clinical execution across our pipeline this quarter, furthering our clinical programs as well as advancing innovative preclinical product candidates to clinical stage,” commented Dr. William (Wei) Cao, founder, Chairman, and CEO of Gracell. “Our autologous and allogeneic T cell therapies are designed to offer differentiated approaches that aim to provide significant improvements...